Table 1

Characteristics of patients who took the subcutaneous methotrexate (scMTX) strategy step or the (next) ciclosporin strategy step

scMTX strategy stepCiclosporin strategy step
CharacteristicTotal (n=57)AE (n=21)IE (n=36)Total (n=40)AE (n=20)IE (n=20)
Female gender, %*44 (77)17 (81)27 (75)30 (75)16 (80)14 (70)
Age, years*54 (16)53 (13)54 (17)52 (14)51 (11)53 (16)
Weight, kg*65 (26)69 (19)62 (29)64 (30)66 (26)62 (35)
ESR, mm/first hour23 (15)28 (19)20 (11)24 (19)27 (24)21 (12)
CRP, mg/litre12 (21)17 (31)10 (13)12 (16)12 (12)13 (20)
RF+, %*31 (54)13 (62)18 (50)23 (58)14 (70)9 (45)
Morning stiffness, min32 (49)50 (65)22 (32)29 (34)34 (35)24 (33)
VAS general, mm29 (26)35 (31)25 (22)30 (25)33 (27)27 (23)
VAS pain, mm23 (24)27 (27)21 (22)23 (20)25 (23)21 (18)
TJC4 (6)5 (6)4 (5)4 (5)3 (4)5 (6)
SJC4 (5)5 (6)4 (4)3 (4)3 (3)4 (5)
DAS283.9 (1.3)4.2 (1.7)3.8 (1.0)3.8 (1.1)3.7 (1.2)3.8 (1.0)
SHS1.6 (4.6)0.7 (1.2)2.1 (5.7)4.2 (9.5)4.1 (8.9)4.3 (10.2)
MTX dose, mg/week28 (4)25 (7)30 (0)28 (6)26 (8)30 (0)
Time until step (no. visits)12 (5)14 (7)11 (4)15 (5)16 (7)14 (3)
  • Data represent the moment the strategy step was taken (except for age, gender, weight and RF, which are baseline data indicated by asterisks). Data show mean (SD) for continuous variables and number of patients (%) for categorical data. MTX dose refers to dose (oral or subcutaneous) of MTX when patients took the strategy step; time until step refers to the number of visits compared to baseline (start of study) after patients took the strategy step; total refers to the total group of patients taking the strategy step.

  • AE, adverse events; CRP, C reactive protein (0–150 mg/litre); DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate (2–140 mm/first hour); IE, insufficient effect; RF+, rheumatoid factor positive, morning stiffness (0–180 min); SHS, Sharp/van der Heijde score; SJC, swollen joint count (0–26); TJC, tender joint count (0–26); VAS, visual analogue scale (0–100 mm).